Evidence map›Paper›PMID 33177934›Full record

ArticleTurkish journal of pharmaceutical sciences2020

Cholinesterase and Tyrosinase Inhibitory Potential and Antioxidant Capacity of

Ufuk Özgen, Sıla Özlem Şener, Karel Šmejkal, Jiri Vaclavik, Fatma Sezer Şenol Denİz, İlkay ErdoĞan Orhan, Emil Svajdlenka, Ahmet C GÖren, Milan ŽemliČka

Abstract read
In one paragraph

Article in Turkish journal of pharmaceutical sciences, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. Article
  2. Article
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Ufuk ÖzgenKaradeniz Technical University Faculty of Pharmacy, Department of Pharmacognosy, Trabzon, Turkey.ORCID https://orcid.org/0000-0001-9839-6717
Sıla Özlem ŞenerKaradeniz Technical University Faculty of Pharmacy, Department of Pharmacognosy, Trabzon, Turkey.ORCID https://orcid.org/0000-0001-7679-7165
Karel ŠmejkalUniversity of Veterinary and Pharmaceutical Sciences Brno, Faculty of Pharmacy, Department of Natural Drugs, Brno, Czechia.ORCID https://orcid.org/0000-0002-4336-7924
Jiri VaclavikUniversity of Veterinary and Pharmaceutical Sciences Brno, Faculty of Pharmacy, Department of Natural Drugs, Brno, Czechia.ORCID https://orcid.org/0000-0002-8928-6628
Fatma Sezer Şenol DenİzGazi University Faculty of Pharmacy, Department of Pharmacognosy, Ankara, Turkey.ORCID https://orcid.org/0000-0002-5850-9841
İlkay ErdoĞan OrhanGazi University Faculty of Pharmacy, Department of Pharmacognosy, Ankara, Turkey.ORCID https://orcid.org/0000-0002-7379-5436
Emil SvajdlenkaUniversity of Veterinary and Pharmaceutical Sciences Brno, Faculty of Pharmacy, Department of Natural Drugs, Brno, Czechia.ORCID https://orcid.org/0000-0002-4876-6297
Ahmet C GÖrenBezmialem Vakıf University Faculty of Pharmacy, Department of Chemistry, İstanbul, Turkey.ORCID https://orcid.org/0000-0002-5470-130X
Milan ŽemliČkaUniversity of Veterinary and Pharmaceutical Sciences Brno, Faculty of Pharmacy, Department of Natural Drugs, Brno, Czechia.ORCID https://orcid.org/0000-0001-9680-2865

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

objectivesThe scope of the present study was to specify the therapeutic potential for neurodegenerative diseases through evaluating cholinesterase and tyrosinase (TYR) inhibitory and antioxidant activity of MATERIALS AND

methodsThe methanol extract (ME) of LV and the chloroform, ethyl acetate (EtOAC), and aqueous fractions obtained from it were used for biological activity and isolation studies. The ME and all fractions were tested for their acetylcholinesterase (AChE), butyrylcholinesterase (BChE), and TYR inhibitory and antioxidant potentials using ELISA microtiter assays. Seven major compounds were isolated from the active EtOAC fraction by semi-preparative high performance liquid chromatography. The structures of the compounds were elucidated by several spectroscopic methods.

resultsMarked AChE inhibitory activity was observed in the EtOAC fraction (6337±1.74%), BChE inhibitory activity in the ME and EtOAC fraction (85.84±3.01% and 83.82±3.93%), total phenol content in the EtOAC fraction (261.59±3.95 mg equivalent of gallic acid/1 g of extract) and total flavonoid contents in the EtOAC fraction (515.54±2.80 mg equivalent of quercetin/1 g of extract), and 2,2-diphenyl-1-picrylhydrazyl radical scavenging activity and ferric-reducing antioxidant power values in the aqueous and EtOAC fractions (92.54±0.67%, 92.11±0.30%; 2.318±0.054, 2.224±0.091, respectively). Accordingly, the isolation studies were carried out on the EtOAC fractions. Compounds 1-7 (gallic acid, (+)-catechin, myricetin 3-O-arabinofuranoside, myricetin 3-O-α-rhamnopyranoside, quercetin 3-O-β-glucopyranoside, quercetin 3-O-arabinofuranoside, and quercetin 3-O-α-rhamnopyranoside, respectively) were isolated from the active EtOAC fraction.

conclusionLV may be a potential herbal source for treatment of neurodegenerative diseases based on its strong antioxidant activity and significant cholinesterase inhibition similar to that of the reference.

Indexed as

AnticholinesteraseHPLCisolationLysimachiatyrosinase

Identifiers

PMID33177934
PMCPMC7650727

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.